We identified a novel association between the MIF variant rs755622, severity of CD and response to anti-TNF therapy in CD patients, and also confirmed the IL17A variant rs2275913 as the strongest and most consistent predictor of response to ADA in CD patients during 30 weeks of treatment. This evidence concerns the gene IL17A and Cowden disease.